Patients with Primary Aldosteronism (PA) Face Increased Cardiovascular Risks and Mortality, Study Finds

Date:

Updated: 7:24 AM, Sat September 16, 2023

Patients with Primary Aldosteronism (PA) Face Increased Cardiovascular Risks and Mortality, Study Finds

Patients with primary aldosteronism (PA), a hormonal disorder that affects the adrenal glands, are at a higher risk of cardiovascular complications and mortality, according to a recent study. The study, which is the first to report the incidence of cardiovascular events and all-cause mortality in coronary artery disease-naive patients with PA, found that after a mean follow-up period of 5.8 years, the incidence rate of new-onset composite cardiovascular events was 10.9 per 1000 person-years, and the incidence rate of all-cause mortality was 5.7 per 1000 person-years.

PA is characterized by excessive production of the hormone aldosterone, which leads to high blood pressure and imbalances in the body’s sodium and potassium levels. Previous studies have shown that patients with PA have a higher prevalence of baseline coronary artery disease at diagnosis, as well as an increased risk of long-term cardiovascular morbidity and mortality.

The study also examined the association between kidney function and cardiovascular outcomes in patients with PA. It was found that decreased estimated glomerular filtration rate (eGFR), a measure of kidney function, was independently associated with increased cardiovascular disease and mortality in both the general population and patients with essential hypertension. However, untreated patients with PA had higher eGFR levels compared to patients with essential hypertension, which could mask actual kidney dysfunction in some cases.

The researchers used the newly developed 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to estimate eGFR in patients with PA. This equation, which does not incorporate race as a variable, provides accurate estimations of kidney function and overcomes racial disparities in GFR estimation.

The study also highlighted the importance of prompt nephrology referral and comprehensive evaluations of kidney function in patients with PA, especially those with baseline eGFR levels below 85 mL/min/1.73 m. Successful treatment of PA, such as adrenalectomy or targeted medications, has been shown to alleviate long-term progressive kidney injury caused by excessive aldosterone secretion.

While the study has some limitations and cannot establish a causal relationship between baseline eGFR and cardiovascular outcomes, it sheds light on the increased cardiovascular risks and mortality faced by patients with PA. The findings reinforce the need for early detection, comprehensive management, and individualized treatment strategies for this patient population.

In conclusion, patients with primary aldosteronism (PA) have an increased risk of cardiovascular complications and mortality. A recent study found that these patients have a higher prevalence of baseline coronary artery disease at diagnosis and a higher risk of long-term cardiovascular morbidity and mortality. The study also highlighted the importance of prompt nephrology referral and comprehensive evaluations of kidney function in patients with PA. Successful treatment of PA has been shown to alleviate long-term progressive kidney injury. These findings contribute to a better understanding of the cardiovascular risks faced by patients with PA and emphasize the need for individualized management strategies.

Frequently Asked Questions (FAQs) Related to the Above News

What is primary aldosteronism (PA)?

Primary aldosteronism (PA) is a hormonal disorder characterized by excessive production of the hormone aldosterone, leading to high blood pressure and imbalances in the body's sodium and potassium levels.

What are the cardiovascular risks associated with primary aldosteronism?

Patients with primary aldosteronism (PA) face increased cardiovascular risks, including a higher prevalence of baseline coronary artery disease at diagnosis and an increased risk of long-term cardiovascular morbidity and mortality.

What did the recent study on primary aldosteronism (PA) find?

The recent study found that patients with primary aldosteronism (PA) had a higher incidence rate of new-onset composite cardiovascular events and all-cause mortality compared to the general population. The study also examined the association between kidney function and cardiovascular outcomes in PA patients.

What is the association between kidney function and cardiovascular outcomes in patients with primary aldosteronism?

The study found that decreased estimated glomerular filtration rate (eGFR), a measure of kidney function, was independently associated with increased cardiovascular disease and mortality in patients with primary aldosteronism (PA) as well as in the general population. However, untreated PA patients had higher eGFR levels compared to patients with essential hypertension, potentially masking kidney dysfunction in some cases.

Did the study provide recommendations for managing primary aldosteronism (PA)?

Yes, the study highlighted the importance of prompt nephrology referral and comprehensive evaluations of kidney function in patients with primary aldosteronism (PA). Successful treatment of PA, such as adrenalectomy or targeted medications, has been shown to alleviate long-term progressive kidney injury caused by excessive aldosterone secretion.

Can the study establish a causal relationship between baseline kidney function and cardiovascular outcomes?

No, the study has limitations and cannot establish a causal relationship between baseline estimated glomerular filtration rate (eGFR) and cardiovascular outcomes. However, it provides important insights into the increased cardiovascular risks and mortality faced by patients with primary aldosteronism (PA).

What are the implications of the study for managing patients with primary aldosteronism (PA)?

The findings of the study reinforce the need for early detection, comprehensive management, and individualized treatment strategies for patients with primary aldosteronism (PA). Prompt nephrology referral and evaluations of kidney function are important considerations, particularly in cases where baseline eGFR levels are below 85 mL/min/1.73 m. Successful treatment of PA has been shown to alleviate long-term progressive kidney injury caused by excessive aldosterone secretion.

What is the significance of the study's use of the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation?

The study used the newly developed 2021 CKD-EPI equation to estimate estimated glomerular filtration rate (eGFR) in patients with primary aldosteronism (PA). This equation provides accurate estimations of kidney function and helps overcome racial disparities in GFR estimation, as it does not incorporate race as a variable.

Why is early detection and individualized treatment important for primary aldosteronism (PA)?

Early detection and individualized treatment strategies are important for primary aldosteronism (PA) because patients with PA face increased cardiovascular risks and mortality. Prompt management can help alleviate long-term progressive kidney injury caused by excessive aldosterone secretion in patients with PA.

What is the takeaway from the study?

The study highlights the increased cardiovascular risks and mortality faced by patients with primary aldosteronism (PA). It emphasizes the need for early detection, prompt nephrology referral, comprehensive evaluations of kidney function, and individualized treatment strategies for this patient population.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Rohan Desai
Rohan Desai
Rohan Desai is a health-conscious author at The Reportify who keeps you informed about important topics related to health and wellness. With a focus on promoting well-being, Rohan shares valuable insights, tips, and news in the Health category. He can be reached at rohan@thereportify.com for any inquiries or further information.

Share post:

Subscribe

Popular

More like this
Related

Senior Conservative Official Steps Aside in UK Election Betting Scandal

Senior Conservative official steps aside in UK election betting scandal, as regulator probes possible use of privileged information. Prime Minister faces criticism.

Police Detain Five Over Drug-Like Substance in Pune Bar, India

Police in Pune detain five individuals after a viral video shows drug-like substance at a bar. Two police officers suspended over late-night party violation.

India Boosts Naval Strength with New Kalvari-class Submarine Deal Valued at ₹35,000 Crore

India boosts naval strength with a new Kalvari-class submarine deal worth ₹35,000 crore, enhancing underwater capabilities for maritime security.

Special Counsel Seeks Gag Order on Trump Over FBI Threat Claim

Special Counsel seeks gag order on Trump over FBI threat claim. Controversy erupts as legal battle intensifies.